The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). PRM-151 is a recombinant (lab-made) version of the protein pentraxin-2. This protein acts on immune cells called macrophages; it can activate these cells to…
PRM-151 Receives FDA Breakthrough Therapy Designation for IPF Treatment
Esbriet Safe and Effective for Patients with Advanced Idiopathic Pulmonary Fibrosis, Trial Suggests
A post-hoc analysis of the Phase 3 RECAP trial shows that long-term treatment with Esbriet (pirfenidone) is safe and similarly effective in patients with advanced idiopathic pulmonary fibrosis (IPF) as in those with less advanced disease. The study, “Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis,”…
High levels of PD-L1 protein were found in the most aggressive fibroblasts that drive idiopathic pulmonary fibrosis (IPF) progression, making the protein — whose levels are increased in cancer cells to shield a tumor from the immune system — a potential new therapeutic target, a study suggests. The study, “…
This year’s edition of Broadway Belts For PFF! — a benefit event for the Pulmonary Fibrosis Foundation (PFF) — raised a record $400,000 to help fund pulmonary fibrosis (PF) research and patient programs. The evening of music, comedy, and performances at New York’s Edison Ballroom was hosted by Broadway…
Following the diagnosis of a life-threatening illness, it is hard to put into words the gamut of emotions a patient might feel. This is true at the time of diagnosis and throughout the disease progression, as emotions ebb and flow while patients learn to cope. At…
I have been a season ticket holder with the Cleveland Browns football team since it returned to action in the city in 1999 after a hiatus. I am part of a group of 11 men that holds seven seats. We passionately believe in our sports franchise. I felt the urge…
Saracatinib (AZD0530), an investigational oral therapy under development by AstraZeneca, was granted Orphan Drug Designation as a potential treatment for idiopathic pulmonary fibrosis (IPF) by the U.S. Food and Drug…
Exposure to dust in the aftermath of the World Trade Center attacks increased the risk of pulmonary fibrosis (PF) among responders, according to an evaluation of self-reported surveys. Researchers found that higher levels of dust exposure were associated with increased PF incidence. The study, “Pulmonary Fibrosis among World Trade…
I believe that people enter our lives when we need them most. I have always made friends easily, and I make an effort to grow and sustain these relationships. I value my connections and strive to nurture them. I have friendships with people I met while traveling and…
Exposure to silica dust may trigger pulmonary fibrosis (PF) because silica particles block a self-cleansing process used by cells, termed autophagy, which drives cell death in the lungs, a study using both human cells and mice showed. Researchers say the findings may improve…
Your PF Community
Recommended Posts
- How my husband and I changed caregiver roles after his treatment
- Phase 3 trials of Haduvio for chronic cough in IPF expected this year
- In search of a living kidney donor for a fellow lung transplant recipient
- With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients
- How we manage the long commute to my IPF doctor appointments
